Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LRMR 
Larimar Therapeutics Inc (LRMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: LRMR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $20.41
Year Target Price $20.41
| 10 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.7% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 194.00M USD | Price to earnings Ratio - | 1Y Target Price 20.04 |
Price to earnings Ratio - | 1Y Target Price 20.04 | ||
Volume (30-day avg) - | Beta 0.79 | 52 Weeks Range 1.61 - 11.20 | Updated Date 06/29/2025 |
52 Weeks Range 1.61 - 11.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.47% | Return on Equity (TTM) -50.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40384094 | Price to Sales(TTM) - |
Enterprise Value 40384094 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.13 | Shares Outstanding 64027900 | Shares Floating 23586595 |
Shares Outstanding 64027900 | Shares Floating 23586595 | ||
Percent Insiders 1.43 | Percent Institutions 108.14 |
Analyst Ratings
Rating 4.91 | Target Price 20.41 | Buy 1 | Strong Buy 10 |
Buy 1 | Strong Buy 10 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Larimar Therapeutics Inc
Company Overview
History and Background
Larimar Therapeutics, Inc. (LTRX) is a biopharmaceutical company focused on developing treatments for complex rare diseases. Founded in 2013, it has focused primarily on developing therapies for Friedreich's ataxia (FA).
Core Business Areas
- Clinical Development: Focuses on the clinical development of CTI-1601 for the treatment of Friedreich's ataxia, the company's lead clinical asset.
Leadership and Structure
The leadership team includes a CEO (Rolf F. Classon), a Chief Medical Officer (Surbhi Lal), and a CFO. The organizational structure is typical of a biotech company, with departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- CTI-1601: CTI-1601 is Larimar's primary product candidate. It's a recombinant human frataxin (r-hFXN) protein designed to deliver frataxin to the mitochondria of patients with Friedreich's ataxia. Market share is effectively 0 as it is still in clinical trials, the company and its competitors are aiming at capturing 100% of Friedreich's ataxia market. Competitors developing FA treatments include Retrotope and Design Therapeutics (DSRT).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on rare diseases is characterized by high R&D costs, regulatory hurdles, and the potential for high prices due to limited patient populations. Development timelines are long and carry substantial risk.
Positioning
Larimar is positioned as a company specializing in rare disease therapeutics, specifically targeting Friedreich's ataxia. Its competitive advantage lies in its proprietary protein delivery technology and its focus on addressing the underlying cause of FA, rather than just managing the symptoms.
Total Addressable Market (TAM)
The Friedreich's ataxia market is estimated to be worth hundreds of millions of dollars annually. Larimar is positioned to capture a significant share of this market if CTI-1601 is approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (CTI-1601)
- Focus on an unmet medical need
- Strong intellectual property position
Weaknesses
- Single product pipeline
- Dependence on clinical trial success
- Limited revenue generation
- Past clinical holds and regulatory setbacks
Opportunities
- Potential for breakthrough therapy designation
- Expansion into other rare diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical data leading to accelerated approval
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from other FA therapies
- Funding challenges
Competitors and Market Share
Key Competitors
- DSRT
- RTOP
Competitive Landscape
Larimar faces competition from companies developing other therapies for Friedreich's ataxia. Its competitive advantage lies in the targetted treatment approach of CTI-1601.
Growth Trajectory and Initiatives
Historical Growth: Larimar's historical growth has been primarily in terms of its clinical development pipeline and its fundraising efforts. No substantial revenue growth has occurred.
Future Projections: Future growth is contingent on the success of CTI-1601 in clinical trials and its subsequent regulatory approval. Analyst projections vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include continuing clinical trials for CTI-1601, securing additional funding, and engaging with regulatory agencies.
Summary
Larimar Therapeutics is a high-risk, high-reward biopharmaceutical company focused on developing a treatment for Friedreich's ataxia. Success hinges on the clinical trials of CTI-1601 and subsequent regulatory approvals. The company is financially sound based on recent reports, but investors should be aware of the inherent risk associated with drug development and potential regulatory challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Company website
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Larimar Therapeutics Inc
Exchange NASDAQ | Headquaters Bala Cynwyd, PA, United States | ||
IPO Launch date 2014-06-19 | CEO, President & Director Dr. Carole S. Ben-Maimon M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | Website https://larimartx.com |
Full time employees 65 | Website https://larimartx.com | ||
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.